Mecapegfilgrastim in Chemotherapy-Induced Neutropenia: A Profile of Its Use in China-Reference-Cited by-同舟云学术

Mecapegfilgrastim in Chemotherapy-Induced Neutropenia: A Profile of Its Use in China

Published:2019-09-05 Issue:10 Volume:39 Page:1009-1018
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Al-Salama Zaina T.,Keam Susan J.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s40261-019-00836-y.pdf

Reference25 articles.

1. Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med. 2006;354(19):2034–45.

2. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: myeloid growth factors (version 2.2018). 2018. http://www.nccn.org . Accessed 23 Jul 2019.

3. Klastersky J, De Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol. 2016;27(Suppl 5):v111–8.

4. Mitchell S, Li X, Woods M, et al. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: a systematic review. J Oncol Pharm Pract. 2016;22(5):702–16.

5. Morishita M, Leonard RC. Pegfilgrastim; a neutrophil mediated granulocyte colony stimulating factor-expanding uses in cancer chemotherapy. Expert Opin Biol Ther. 2008;8(7):993–1001.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A multicenter, prospective, non‐interventional real‐world study to assess the effectiveness of mecapegfilgrastim in preventing neutropenia in patients with gastrointestinal cancer;Immunity, Inflammation and Disease;2024-08

2. Role of recombinant human granulocyte colony-stimulating factor in development of cancer-associated venous thromboembolism in lung cancer patients who undergo chemotherapy;Frontiers in Immunology;2024-05-31

3. Cost-effectiveness analysis of mecapegfilgrastim and recombinant human granulocyte stimulating factor for primary prophylaxis of chemotherapy-induced neutropenia in non-small cell lung cancer;Int. Journal of Clinical Pharmacology and Therapeutics;2024-03-01

4. The efficacy of Mecapegfilgrastim therapy in the primary prevention of concurrent chemoradiotherapy-induced neutropenia;Journal of Radiation Research and Applied Sciences;2023-09

5. Long-acting versus short-acting granulocyte colony-stimulating factors among cancer patients after chemotherapy in China;Medicine;2021-12-23